APABLAZA SALINAS, MAURICIO IVÁN
Preferred name
APABLAZA SALINAS, MAURICIO IVÁN
Main Affiliation
Email
mapablaza@udd.cl
ORCID
0000-0003-1306-3791
Scopus Author ID
56845856600
43 results
Now showing 1 - 10 of 43
- Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Multimorbidity profile among cancer-related hospitalization events in younger and older patients: a large-scale nationwide cross-sectional study(GITHUB, 2026) ;Sanhueza Condell Cristobal Tomas ;CARLA ANDREA CAMPAÑA CASTILLO; ; - Some of the metrics are blocked by yourconsent settings
Item type:Product, - Some of the metrics are blocked by yourconsent settings
Item type:Product, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Geospatial disparities in post-pandemic SARS-CoV-2 vaccination: Evidence from Chile beyond the national success(Public Library of Science (PLoS), 2026-07-27) ;Ramírez-Santana, Muriel ;Correa, Juan; ;Canales, Luis - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 28 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Are migrants in/from emerging economies more entrepreneurial than natives?(2021); ; ; Veronica Arriagada<jats:title>Abstract</jats:title><jats:p>The academic debate in migrant entrepreneurship has mainly focused on movements from emerging economies into developed economies. Anecdotal evidence has suggested that the highest impact is generated by migrants in/from emerging economies. To extend this academic discussion in the Latin-American context, this study investigates why migrants are more entrepreneurial than natives. By adopting the human capital and the institutional approach, we theorize that individual and environmental conditions produce selection/discrimination effects in the host labour market. Consequently, these effects influence migrants’ decision to become entrepreneurs. We tested our hypotheses using a sample of 13,368 adults between the ages of 18–64 based across the 16 Chilean regions. Our results showed that being a high-skilled migrant in a dynamic emerging economy is not a guarantee of success in the labour market, but it is a determinant of international and necessity-driven entrepreneurship. Several implications and a provocative discussion emerged from these findings.</jats:p>3Scopus© Citations 32 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile(2022); ;Gloria Icaza; ; <jats:p>Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.</jats:p>6Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 10